Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

来源: Nasdaq GlobeNewswire / 27 11月 2023 07:00:00   America/New_York